Uncover key drivers, emerging technologies, and competitive movements shaping the worker heat stress monitoring wearable market from 2026–2035 with trusted insights from The Business Research Company
How much is the Inhaler Corticosteroid Device Market valued at in 2026, and what valuation is forecast for 2030?
The inhaler corticosteroid device market has demonstrated robust growth in recent years. It is projected to expand from $16.83 billion in 2025 to $17.98 billion in 2026, at a compound annual growth rate (CAGR) of 6.8%. This historical growth can be attributed to factors such as the increasing prevalence of asthma and COPD, heightened awareness regarding inhaler therapies, government initiatives for respiratory health, advancements in metered-dose inhalers, and the expansion of hospital and homecare facilities.
The inhaler corticosteroid device market is projected for substantial expansion over the upcoming years. This market is anticipated to reach $23.18 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. Key factors contributing to this projected growth include the incorporation of AI and IoT into inhaler technologies, the creation of environmentally friendly inhalers, the broader availability of telehealth services, tailored medication dispensing, and increasing consumer interest in developing economies. Noteworthy trends during this period are expected to encompass the integration of smart inhalers, customized dosage management, monitoring facilitated by telehealth, sustainable and eco-friendly device designs, and innovative aerosol delivery methods.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25794&type=smp
What Drivers Are Influencing The Growth Of The Inhaler Corticosteroid Device Market?
The rising occurrence of respiratory diseases is projected to drive the growth of the inhaler corticosteroid device market moving forward. Respiratory diseases are a spectrum of conditions affecting the lungs and airways, impeding proper and efficient breathing for individuals. The increase in these diseases is attributed to escalating air pollution, which exposes people to harmful particles that damage lung tissue and can initiate chronic conditions such as asthma and bronchitis. Inhaler corticosteroid devices are utilized in the treatment of respiratory diseases by delivering anti-inflammatory medication directly to the lungs, which helps in reducing inflammation and improving breathing. For instance, in June 2025, the Office for Health Improvement and Disparities, a UK-based government department, indicated that in the financial year ending 2024, England recorded 854,922 emergency hospital admissions for respiratory diseases. This figure corresponds to a rate of 1,428 (ranging from 1,424 to 1,432) per 100,000 population, marking a 7% increase when compared to the preceding year. Therefore, the increasing prevalence of respiratory diseases is a key factor boosting the expansion of the inhaler corticosteroid device market.
What Segments Are Included Within The Inhaler Corticosteroid Device Market?
The inhaler corticosteroid device market covered in this report is segmented –
1) By Product Type: Metered-Dose Inhalers, Dry Powder Inhalers, Soft Mist Inhalers
2) By Formulation Type: Fluticasone Propionate, Budesonide, Beclomethasone, Mometasone Furoate
3) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Direct Sales, Hospital Pharmacies
4) By Application: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Other Applications
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Metered-Dose Inhalers: Conventional Metered-Dose Inhalers, Breath-Actuated Metered-Dose Inhalers, Spacer-Integrated Metered-Dose Inhalers
2) By Dry Powder Inhalers: Single-Dose Dry Powder Inhalers, Multi-Dose Dry Powder Inhalers, Reservoir Dry Powder Inhalers
3) By Soft Mist Inhalers: Manual Soft Mist Inhalers, Battery-Operated Soft Mist Inhalers
What Trends Are Expected To Impact The Competitive Landscape Of The Inhaler Corticosteroid Device Market?
Leading companies in the inhaler corticosteroid device market are concentrating on developing innovative solutions, such as rescue inhalers that combine albuterol and budesonide, to enhance treatment effectiveness and provide patients with a more convenient, dual-action therapy in a single device. An inhaler integrating albuterol and budesonide functions as a dual-action rescue inhaler, delivering both a bronchodilator (albuterol) to rapidly open airways and a corticosteroid (budesonide) to mitigate inflammation, offering quick symptom relief and long-term control of asthma from one device. For instance, in January 2024, AstraZeneca PLC, a UK-based pharmaceutical company, launched AIRSUPRA, which is the first and only FDA-approved rescue inhaler combining albuterol and budesonide for adults with asthma. This inhaler is designed for as-needed use to both alleviate acute bronchoconstriction symptoms and reduce airway inflammation, thereby lowering the risk of severe asthma exacerbations. It signifies a novel approach by merging a short-acting beta2-agonist (albuterol) with an inhaled corticosteroid (budesonide) in a single inhaler, approved based on clinical trials that demonstrated its superior efficacy over albuterol alone in preventing asthma attacks.
Who Are The Core Companies Influencing Trends In The Inhaler Corticosteroid Device Market?
Major companies operating in the inhaler corticosteroid device market are AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Teijin Pharma Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Mundipharma International Limited, Lupin Limited, Zydus Lifesciences Limited, Recipharm AB, Glenmark Pharmaceuticals Limited, Orion Corporation, Beximco Pharmaceuticals Limited, PARI Medical Holding GmbH
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/inhaler-corticosteroid-device-global-market-report
Which Geographic Areas Are Emerging As Strong Markets For The Inhaler Corticosteroid Device Market?
North America was the largest region in the inhaler corticosteroid device market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhaler corticosteroid device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Inhaler Corticosteroid Device Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25794&type=smp
Browse Through More Reports Similar to the Global Inhaler Corticosteroid Device Market 2026, By The Business Research Company
Implantable Infusion Pumps Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/implantable-infusion-pumps-global-market-report
Intravenous Infusion Pumps Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/intravenous-infusion-pumps-global-market-report
Ambulatory Iv Infusion Pumps Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/ambulatory-iv-infusion-pumps-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company